Company Snapshot: EMIS  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Emisphere Technologies, Inc. to Hold Conference Call to Discuss Fourth Quarter and Year End 2005 Financial Results

    TARRYTOWN, N.Y., March 9 /PRNewswire-FirstCall/ -- Emisphere Technologies,
Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its 2005 fourth
quarter and year end financial results on Tuesday, March 14, 2006, beginning
at 11:00 a.m. Eastern Time (8:00 a.m. Pacific). A replay of the call will be
accessible approximately two hours following the end of the call and will be
archived through March 21, 2006.

    The live conference call dial-in number is: 1-888-695-7895 (U.S./Canada)
                                                1-706-679-3799 (International)
    The live conference call ID number is:      6454497
    To access a replay of the call:             1-800-642-1687 (U.S./Canada)
                                                1-706-645-9291 (International)
                                                Conference ID / Pin:6454497

    Emisphere will simultaneously be webcasting this teleconference. To access
the live broadcast in listen-only mode or the subsequently archived recording
please go to the Investor Relations portion of the Company's website at:
http://www.emisphere.com/ir.asp.
    Please visit the site at least five minutes prior to start time for
instructions.

    About Emisphere Technologies, Inc.
    Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the
oral delivery of otherwise injectable drugs. Emisphere's business strategy is
to develop oral forms of injectable drugs, either alone or with corporate
partners, by applying its proprietary eligen(R) technology to those drugs or
licensing its eligen(R) technology to partners who typically apply it directly
to their marketed drugs. Emisphere's eligen(R) technology has enabled the oral
delivery of proteins, peptides, macromolecules and charged organics. Emisphere
and its partners have advanced oral formulations or prototypes of salmon
calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and
cromolyn sodium into clinical trials. Emisphere has strategic alliances with
world-leading pharmaceutical companies. For further information, please visit
http://www.emisphere.com.


SOURCE Emisphere Technologies, Inc.




Back to Topback to top

Related links:
  • http://www.emisphere.com
  • http://www.emisphere.com/ir.asp
    CONTACT:
    Elliot M. Maza, CPA, J.D., Chief Financial
    Officer of Emisphere Technologies, Inc., +1-914-785-4703; or Dan
    Budwick of BMC Communications for Emisphere Technologies, Inc.,
    +1-212-477-9007 ext. 14